{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:04:55Z","timestamp":1765011895675,"version":"3.46.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,6]]},"DOI":"10.7759\/cureus.98560","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:02:16Z","timestamp":1765011736000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Long-Term Shichimotsukokato Administration on the eGFR Slope in Patients With Chronic Kidney Disease: A Retrospective Single-Arm Study"],"prefix":"10.7759","author":[{"given":"Kazushi","family":"Uneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadamichi","family":"Mitsuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeatsu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.08.003","article-title":"Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate","volume":"90","author":"Matsushita K","year":"2016","unstructured":"Matsushita K, Chen J, Sang Y, et al.. Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Kidney Int. 2016, 90:1109-14. 10.1016\/j.kint.2016.08.003","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.09.015","article-title":"Cardiovascular events and death in Japanese patients with chronic kidney disease","volume":"91","author":"Tanaka K","year":"2017","unstructured":"Tanaka K, Watanabe T, Takeuchi A, et al.. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017, 91:227-34. 10.1016\/j.kint.2016.09.015","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita K","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, et al.. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010, 375:2073-81. 10.1016\/s0140-6736(10)60674-5","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000568","article-title":"Sodium-glucose cotransporter 2 inhibitors and kidney outcomes across the spectrum of kidney disease. A systematic review and meta-analysis","volume":"20","author":"Spiazzi BF","year":"2024","unstructured":"Spiazzi BF, Piccoli GF, Wayerbacher LF, et al.. Sodium-glucose cotransporter 2 inhibitors and kidney outcomes across the spectrum of kidney disease. A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2024, 20:39-49. 10.2215\/CJN.0000000000000568","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-023-02376-4","article-title":"eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database","volume":"27","author":"Itano S","year":"2023","unstructured":"Itano S, Kanda E, Nagasu H, Nangaku M, Kashihara N. eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database. Clin Exp Nephrol. 2023, 27:847-56. 10.1007\/s10157-023-02376-4","journal-title":"Clin Exp Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker LA","year":"2023","unstructured":"Inker LA, Collier W, Greene T, et al.. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023, 29:1867-76. 10.1038\/s41591-023-02418-0","journal-title":"Nat Med"},{"key":"ref8","unstructured":"European Medicines Agency. Qualification Opinion for GFR slope as a Validated Surrogate Endpoint for RCT in CKD. (2025). Accessed: n.d: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-advice-protocol-assistance\/opi...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117127","article-title":"Efficacy and safety of the traditional herbal medication Chai-Ling-Tang (in China), Siryung-tang (in Republic of Korea) or Sairei-To (in Japan)","volume":"319","author":"Bailly C","year":"2024","unstructured":"Bailly C. Efficacy and safety of the traditional herbal medication Chai-Ling-Tang (in China), Siryung-tang (in Republic of Korea) or Sairei-To (in Japan). J Ethnopharmacol. 2024, 319:117127. 10.1016\/j.jep.2023.117127","journal-title":"J Ethnopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/tkm2.1418","article-title":"Current situation and future issues with Kampo medicine: a survey of Japanese physicians","volume":"11","author":"Uneda K","year":"2024","unstructured":"Uneda K, Yoshino T, Ito H, Imoto S, Nogami T. Current situation and future issues with Kampo medicine: a survey of Japanese physicians. Tradit Kampo Med. 2024, 11:156-66. 10.1002\/tkm2.1418","journal-title":"Tradit Kampo Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11418-015-0945-1","article-title":"The renoprotective effect of shichimotsukokato on hypertension-induced renal dysfunction in spontaneously hypertensive rats","volume":"70","author":"Ma Y","year":"2016","unstructured":"Ma Y, Fujimoto M, Watari H, Kimura M, Shimada Y. The renoprotective effect of shichimotsukokato on hypertension-induced renal dysfunction in spontaneously hypertensive rats. J Nat Med. 2016, 70:152-62. 10.1007\/s11418-015-0945-1","journal-title":"J Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b12-00479","article-title":"Protective effects of Shichimotsu-koka-To on irreversible Thy-1 nephritis","volume":"36","author":"Ono T","year":"2013","unstructured":"Ono T, Kamikado K, Morimoto T. Protective effects of Shichimotsu-koka-To on irreversible Thy-1 nephritis. Biol Pharm Bull. 2013, 36:41-7. 10.1248\/bpb.b12-00479","journal-title":"Biol Pharm Bull"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02497-4","article-title":"Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023","volume":"28","year":"2024","unstructured":"Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin Exp Nephrol. 2024, 28.473-95. 10.1007\/s10157-024-02497-4","journal-title":"Clin Exp Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02331-8","article-title":"Key highlights of the Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)","volume":"48","author":"Ohya Y","year":"2025","unstructured":"Ohya Y, Sakima A, Arima H, et al.. Key highlights of the Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Hypertens Res. 2025, 48:2500-11. 10.1038\/s41440-025-02331-8","journal-title":"Hypertens Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02514-6","article-title":"Guidelines for clinical evaluation of chronic kidney disease in early stages. AMED research on regulatory science of pharmaceuticals and medical devices","volume":"28","author":"Sugawara Y","year":"2024","unstructured":"Sugawara Y, Kanda E, Hamano T, et al.. Guidelines for clinical evaluation of chronic kidney disease in early stages. AMED research on regulatory science of pharmaceuticals and medical devices. Clin Exp Nephrol. 2024, 28:847-65. 10.1007\/s10157-024-02514-6","journal-title":"Clin Exp Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.11339\/jtm.26.230","article-title":"Basic study and clinical practice of Kampo medicines in chronic kidney disease (CKD): chronic glomerulonephritis and nephrosclerosis","volume":"26","author":"Ono T","year":"2009","unstructured":"Ono T, Makino T. Basic study and clinical practice of Kampo medicines in chronic kidney disease (CKD): chronic glomerulonephritis and nephrosclerosis. J Tradit Med. 2009, 26:230-4. 10.11339\/jtm.26.230","journal-title":"J Tradit Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061463","article-title":"A systematic review of phytochemistry, pharmacology and pharmacokinetics on astragali radix: implications for astragali radix as a personalized medicine","volume":"20","author":"Guo Z","year":"2019","unstructured":"Guo Z, Lou Y, Kong M, Luo Q, Liu Z, Wu J. A systematic review of phytochemistry, pharmacology and pharmacokinetics on astragali radix: implications for astragali radix as a personalized medicine. Int J Mol Sci. 2019, 20:1463. 10.3390\/ijms20061463","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.117848","article-title":"Advanced researches of traditional uses, phytochemistry, pharmacology, and toxicology of medical Uncariae Ramulus Cum Uncis","volume":"325","author":"Cao R","year":"2024","unstructured":"Cao R, Wang Y, Zhou Y, et al.. Advanced researches of traditional uses, phytochemistry, pharmacology, and toxicology of medical Uncariae Ramulus Cum Uncis. J Ethnopharmacol. 2024, 325:117848. 10.1016\/j.jep.2024.117848","journal-title":"J Ethnopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11418-011-0625-8","article-title":"Anti-hypertensive effects of shichimotsukokato in 5\/6 nephrectomized Wistar rats mediated by the DDAH-ADMA-NO pathway","volume":"66","author":"Bai F","year":"2012","unstructured":"Bai F, Makino T, Ono T, Mizukami H. Anti-hypertensive effects of shichimotsukokato in 5\/6 nephrectomized Wistar rats mediated by the DDAH-ADMA-NO pathway. J Nat Med. 2012, 66:583-90. 10.1007\/s11418-011-0625-8","journal-title":"J Nat Med"},{"key":"ref20","article-title":"Huangqi (astragalus) decoction ameliorates diabetic nephropathy via IRS1-PI3K-GLUT signaling pathway","volume":"10","author":"Chen X","year":"2018","unstructured":"Chen X, Wang H, Jiang M, Zhao J, Fan C, Wang Y, Peng W. Huangqi (astragalus) decoction ameliorates diabetic nephropathy via IRS1-PI3K-GLUT signaling pathway. Am J Transl Res. 2018, 10:2491-501.","journal-title":"Am J Transl Res"},{"key":"ref21","article-title":"Astragaloside effect on TGF-\u03b21, SMAD2\/3, and \u03b1-SMA expression in the kidney tissues of diabetic KKAy mice","volume":"8","author":"Wang Y","year":"2015","unstructured":"Wang Y, Lin C, Ren Q, Liu Y, Yang X. Astragaloside effect on TGF-\u03b21, SMAD2\/3, and \u03b1-SMA expression in the kidney tissues of diabetic KKAy mice. Int J Clin Exp Pathol. 2015, 8:6828-34.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177289","article-title":"Hirsutine mitigates ferroptosis in podocytes of diabetic kidney disease by downregulating the p53\/GPX4 signaling pathway","volume":"991","author":"Pei Z","year":"2025","unstructured":"Pei Z, Chen Y, Zhang Y, et al.. Hirsutine mitigates ferroptosis in podocytes of diabetic kidney disease by downregulating the p53\/GPX4 signaling pathway. Eur J Pharmacol. 2025, 991:177289. 10.1016\/j.ejphar.2025.177289","journal-title":"Eur J Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S170840","article-title":"Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice","volume":"12","author":"Wang X","year":"2018","unstructured":"Wang X, Gao Y, Tian N, Zou D, Shi Y, Zhang N. Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice. Drug Des Devel Ther. 2018, 12:2431-42. 10.2147\/DDDT.S170840","journal-title":"Drug Des Devel Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115521","article-title":"Isorhynchophylline ameliorates paraquat-induced acute kidney injury by attenuating oxidative stress and mitochondrial damage via regulating toll-interacting expression","volume":"420","author":"Zheng Q","year":"2021","unstructured":"Zheng Q, Zhang Y, Zhao Z, Shen H, Zhao H, Zhao M. Isorhynchophylline ameliorates paraquat-induced acute kidney injury by attenuating oxidative stress and mitochondrial damage via regulating toll-interacting expression. Toxicol Appl Pharmacol. 2021, 420:115521. 10.1016\/j.taap.2021.115521","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3937\/kampomed.67.347","article-title":"The combined use of Shinbuto and Boiogito has an inhibitory effect on the progression of chronic kidney disease with minimal proteinuria","volume":"67","author":"Shoji T","year":"2016","unstructured":"Shoji T, Takahashi M. The combined use of Shinbuto and Boiogito has an inhibitory effect on the progression of chronic kidney disease with minimal proteinuria. Kampo Med. 2016, 67:347-53. 10.3937\/kampomed.67.347","journal-title":"Kampo Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3937\/kampomed.63.98","article-title":"Four cases of chronic renal failure successfully treated with Astragalus","volume":"63","author":"Nagasaka K","year":"2012","unstructured":"Nagasaka K, Fukuda H, Watanabe T, Nagata Y. Four cases of chronic renal failure successfully treated with Astragalus. Kampo Med. 2012, 63:98-102. 10.3937\/kampomed.63.98","journal-title":"Kampo Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/tkm2.70013","article-title":"Long-term effect of the Japanese herbal Kampo medicine extracts on renal function: a single center propensity score analysis","volume":"12","author":"Sawai K","year":"2025","unstructured":"Sawai K, Yamazaki T, Mine T. Long-term effect of the Japanese herbal Kampo medicine extracts on renal function: a single center propensity score analysis. Tradit Kampo Med. 2025, 12:151-9. 10.1002\/tkm2.70013","journal-title":"Tradit Kampo Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81115","article-title":"Remission induced by Shichimotsukokato in an older adult with nephrotic syndrome secondary to diabetic kidney disease: a case report","volume":"17","author":"Uneda K","year":"2025","unstructured":"Uneda K, Kikuchi T, Mori M, Kaneko A, Tahara E. Remission induced by Shichimotsukokato in an older adult with nephrotic syndrome secondary to diabetic kidney disease: a case report. Cureus. 2025, 17:e81115. 10.7759\/cureus.81115","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.07.032","article-title":"Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus","volume":"50","author":"Ahmed MS","year":"2007","unstructured":"Ahmed MS, Hou SH, Battaglia MC, Picken MM, Leehey DJ. Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus. Am J Kidney Dis. 2007, 50:1028-32. 10.1053\/j.ajkd.2007.07.032","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358542-effectiveness-of-long-term-shichimotsukokato-administration-on-the-egfr-slope-in-patients-with-chronic-kidney-disease-a-retrospective-single-arm-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:02:17Z","timestamp":1765011737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358542-effectiveness-of-long-term-shichimotsukokato-administration-on-the-egfr-slope-in-patients-with-chronic-kidney-disease-a-retrospective-single-arm-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.98560","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,6]]}}}